Company Description
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States.
The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.
It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer.
The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications.
G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
| Country | United States |
| Founded | 2008 |
| IPO Date | May 17, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | John Bailey |
Contact Details
Address: 700 Park Offices Drive, Suite 200 Research Triangle Park, North Carolina 27709 | |
| Phone | 919 213 9835 |
| Website | g1therapeutics.com |
Stock Details
| Ticker Symbol | GTHX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001560241 |
| CUSIP Number | 3621LQ109 |
| ISIN Number | US3621LQ1099 |
| Employer ID | 26-3648180 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John E. Bailey Jr. | Chief Executive Officer, President and Director |
| Dr. Rajesh K. Malik Ch.B., M.B., M.D. | Chief Medical Officer |
| Mark Avagliano | Chief Business Officer |
| John W. Umstead V | Chief Financial Officer |
| Terry L. Murdock MSc | Chief Operating Officer |
| William C. Roberts | Vice President of Investor Relations and Corporate Communications |
| Monica Roberts Thomas | Chief Legal and People Officer |
| Evan Hicks M.B.A. | Vice President of Marketing |
| Andrew Perry | Chief Commercial Officer |
| Jeff Macdonald | Senior Director of Investor Relations and Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 18, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Sep 18, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Sep 18, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Sep 18, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Sep 18, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Sep 18, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Sep 18, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Sep 18, 2024 | 25-NSE | Filing |
| Sep 18, 2024 | 8-K | Current Report |
| Sep 18, 2024 | SC 14D9/A | Filing |